Public Health Alert: NAFDAC Recalls Dangerous Male Enhancement Supplement

The National Agency for Food and Drug Administration and Control has ordered a voluntary recall of all batches of the male enhancement dietary supplement known as MR.7 SUPER 700000 capsules over serious safety concerns.

In a notice shared on its official page on X on Monday, the agency said the action followed findings from an analysis conducted by the U.S. Food and Drug Administration, which revealed that the product contains undeclared active ingredients.

According to the agency, the capsules were found to contain Sildenafil and Tadalafil—both phosphodiesterase type-5 (PDE-5) inhibitors commonly used in approved medications for the treatment of erectile dysfunction.

NAFDAC explained that the presence of these substances in the supplement means the product is effectively an unapproved drug whose safety and effectiveness have not been established, making it subject to recall.

The agency noted that MR.7 SUPER 700000 capsules are marketed online as a dietary supplement for male enhancement, but emphasised that products containing sildenafil or tadalafil cannot legally be sold as dietary supplements and may pose serious health risks.

It further warned that the undisclosed ingredients make the capsules unsafe because they have not undergone proper regulatory evaluation.

Health authorities also cautioned that the hidden substances could interact dangerously with nitrate-based medications such as Nitroglycerin, which are commonly prescribed for certain heart conditions. Such interactions could trigger a sudden and potentially life-threatening drop in blood pressure.

The agency stressed that individuals with conditions such as diabetes, hypertension, high cholesterol, or heart disease—particularly those taking nitrate medications—may face the highest risk if they consume the product.

NAFDAC has therefore urged members of the public to immediately stop using or distributing MR.7 SUPER 700000 capsules and to return any remaining supplies to the nearest NAFDAC office.

Consumers were also encouraged to report suspected substandard or harmful products, as well as any adverse reactions linked to medicines or medical devices, through the agency’s e-reporting platforms, the Med-Safety mobile app, or via its official email channels.

The agency reaffirmed its commitment to protecting public health through continuous monitoring and regulation of medicines, medical devices and other controlled products circulating within Nigeria.